GlassScriptPhysician profile
Thomas W Abernathy
NPI 1538105697
$7,780.58
in general payments reported to CMS, 2019-2025
45 companies · $1,481 in 2025
The $1,481 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,524 · 2020: $280 · 2021: $842 · 2022: $905 · 2023: $1,173 · 2024: $1,576 · 2025: $1,481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,136 · Education: $93.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,136.24 |
| Education | $93.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $1,166.35 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Abbvie INC. | $1,022.28 | 2019-2025 | Linzess, Viberzi, Creon |
| Janssen Biotech, INC. | $713.22 | 2019-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $635.56 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Pfizer INC. | $396.53 | 2019-2025 | |
| Genzyme Corporation | $385.29 | 2022-2025 | |
| Qol Medical, LLC | $326.39 | 2019-2024 | Sucraid, Sucraid |
| Celgene Corporation | $260.53 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $252.32 | 2019-2025 | Ocaliva |
| Ferring Pharmaceuticals INC. | $231.84 | 2019-2023 | Clenpiq |
| Regeneron Healthcare Solutions, INC. | $159.83 | 2022-2024 | Dupixent |
| Daiichi Sankyo INC. | $153.20 | 2019-2024 | Injectafer |
| Nestle Healthcare Nutrition INC. | $151.96 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $149.52 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $148.90 | 2021-2024 | Givlaari |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $120.17 | 2022-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $108.08 | 2024-2025 | Zenpep |
| Braintree Laboratories, INC. | $99.84 | 2019-2023 | Suflave, Sutab |
| Celltrion USA INC. | $99.60 | 2024-2025 | Vegzelma |
| Organon LLC | $95.94 | 2021-2024 | Renflexis |
| Ironwood Pharmaceuticals, INC | $93.98 | 2019-2023 | Linzess |
| Mallinckrodt Hospital Products INC. | $93.93 | 2022-2024 | Terlivaz |
| Shionogi INC | $88.61 | 2019-2020 | |
| Madrigal Pharmaceuticals | $75.99 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $74.12 | 2024-2025 | Omvoh |
| Amgen INC. | $68.78 | 2021-2023 | Avsola, Amjevita |
| Romark Laboratories, Lc | $62.41 | 2019-2020 | |
| Micro-Tech Endoscopy USA, INC. | $50.50 | 2025 | |
| Fresenius Kabi USA, LLC | $49.71 | 2023-2024 | Idacio |
| Phathom Pharmaceuticals, INC. | $47.64 | 2025 | Voquezna |
| Pharmacosmos Therapeutics INC. | $44.01 | 2024-2025 | Monoferric |
| Redhill Biopharma INC. | $42.18 | 2021 | |
| Gilead Sciences, INC. | $35.07 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $33.84 | 2025 | Tremfya |
| Shire North American Group INC | $30.65 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.58 | 2023 | Cyltezo |
| Allergan, INC. | $26.88 | 2019-2020 | |
| W. L. Gore & Associates, INC. | $26.29 | 2022-2023 | Gore Cardioform Septal Occluder |
| Ucb, INC. | $26.10 | 2019 | |
| Olympus America INC. | $23.04 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $22.38 | 2019 | |
| Capsovision, INC. | $19.86 | 2024 | Capsocam Plus |
| Boston Scientific Corporation | $14.96 | 2024 | Cre Pro |
| Alfasigma USA, INC. | $14.48 | 2020 | |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Abernathy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.